{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-25-000020","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.986979+00:00","generated_at":"2026-05-17T13:20:32.120103+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Werewolf Therapeutics Q2 net loss $18M; WTX-124 data on track for Q4 2025","bullets":["Cash $77.6M as of June 30, 2025, providing runway into Q4 2026.","Net loss $18.0M for Q2 2025 vs $17.2M in Q2 2024; R&D $13.1M, G&A $4.4M.","WTX-124 Phase 1/1b interim data expected Q4 2025 in melanoma and renal cell carcinoma.","Planning FDA engagement in H2 2025 to discuss registrational pathway for cutaneous melanoma.","New candidate WTX-1011 (anti-STEAP1 T-cell engager) announced; additional candidate expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-25-000020","json":"https://secwatch.observer/filing/0001785530-25-000020.json","markdown":"https://secwatch.observer/filing/0001785530-25-000020.md","text":"https://secwatch.observer/filing/0001785530-25-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553025000020/0001785530-25-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553025000020/howl-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:20:32.120103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}